Pharmacotherapy for Hepatic encephalopathy: view of Evidence-Based Medicine

Ming-Hua Zheng1*, Dan-Qin Sun1, Qian Jiang2, Ke-Qing Shi1, Ai-Min Wu3 and Yong-Ping Chen4*

1Department of Infection and Liver Diseases, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China
2Department of Pharmacy, the Second people’s Hospital of Sichuan Province, Sichuan provincial Cancer Hospital, Chengdu 610041, China
3Information Service Department, Library of Wenzhou Medical College, Wenzhou 325000, China

Summary

Hepatic encephalopathy (HE) refers to a complex and reversible neuro-psychiatric syndrome that results from complications of acute or chronic hepatic failure, particularly alcoholic cirrhosis [1,2]. Clinical manifestations of HE can vary widely from minor signs of altered brain function, overt psychiatric, and/or neurological symptoms to deep coma, which will lead to frequent life disruptions, poor quality of life and extensive use of health care resources. It is also an independent risk factor for death [3].

The accumulation of unmetabolized toxins (primarily ammonia) in the brain, false neurotransmitters and neuro-inhibitory substances are believed to be the main mechanisms of HE. Precipitating factors include gastrointestinal bleeding, infections or systemic inflammatory response syndrome, renal and electrolyte disturbances, dehydration, use of psychoactive medications, constipation, excess dietary protein, and acute deterioration of liver function. Therefore, current management of HE focuses on exclusion of other causes of encephalopathy, identification of precipitating factors, resolution of the accumulation of neurotoxic byproducts of protein metabolism (measured by ammonia level) and correction of electrolyte balance [1-3].

The most commonly used therapies for treatment and prevention are non-absorbable disaccharides (NAD), in spite of limited studies evaluating the safety and efficacy, which calls for new therapeutics worldwide. Therefore, we conducted the review of several agents, e.g. rifaximin, L-Ornithine-L-aspartate (LOLA) based on randomized controlled trials (RCTs) of high-quality Jadad scores (≥3), which assessed the degree of randomization, blinding, subject withdrawals and dropouts, to provide effective information for clinical practice.

Rifaximin

Background: Rifaximin, a derivative of rifamycin, has a very low rate of systemic absorption (<0.4%) after oral administration, acts by inhibiting a spectrum of antibacterial ribonuclease acid synthesis. The drug was first introduced in Italy in 1987, and was used as first line therapy for hepatic encephalopathy in Europe, Asia, and Africa. In the United States, however, it was used for the treatment of non-dysenteric diarrhea, but not for HE [2]. During the past decade, numeric studies have identified that rifaximin was at least as safe and as effective as lactulose and other non-absorbable antibiotics, such as neomycin and paromomycin, for the treatment of HE [4-11].

Clinical efficacy of rifaximin: Clinical efficacy was defined as improvement of clinical syndrome, mental state and EEG and significant decrease of ammonia level. A total of five RCTs were registered in our study. The quality scores were listed in Table 1. All the included trials were of high quality. In these studies, two compared rifaximin with lactitol, three with lactulose, one with neomycin and the rest one with placebo (Table 1). The main features of these trials included are shown in Table 2.

In 1993, a randomized, double-blind, double-dummy, controlled trial was designed to compare rifaximin and lactulose for the treatment of patients with stage 1 porto-systemic encephalopathy (PSE) for 3 months. Mental status, ammonia level, asterixis and PSE severity were all improved. However, it concluded that clinical efficacy of rifaximin...
was not superior to lactulose. In an open-label prospective randomized trial conducted in Korea [9], the efficacy and safety of rifaximin was reported to be no better than lactulose (the HE index; rifaximin group (10.0 –> 4.2, p = 0.000); lactulose group (11.3 –> 5.0, p = 0.000). Mas et al. [8] conducted a randomized, double-blind, double-dummy controlled study of rifaximin, 1,200 mg/day (n=50) and lactitol 60 g/ day (n=53) in patients with grade I–III and acute HE for 5-6 days. HE index mental status, asterixis, EEG and ammonia level were evaluated. The results had showed that PSE was decreased to some extent, due to a greater efficacy of blood ammino and EEG abnormalities. The total effectiveness was similar: 81.6% in the rifaximin group and 80.4% in the lactitol group, respectively. It suggested that rifaximin might be a good alternative for patients with acute HE of moderate to severe grade. Another high-quality controlled trial reported that rifaximin was not superior to lactulose [6]. Recently, Nathan M et al. [12] performed a RCT comparing rifaximin (n=140, 550mg, bid for 6 months) with placebo (n=159) in 299 patients. 87.9% of patients in the rifaximin group were 

There were several studies comparing rifaximin with neomycin and other antibiotics. Migliol et al. [13] designed a double-blind, randomized trial with 60 patients in grade 1-2 score at the dose of 1g three times daily. This study indicated that rifaximin, was more effective than neomycin, although the difference was not significant. However, some oral antibiotics are not widespread due to adverse events profiles in the clinical studies.

Even though these studies reported conflicting results, our meta-analysis of rifaximin versus non-absorbale disaccharides in HE [14] concluded that there were no difference between the two regimes.

Adverse events: Rifaximin also has revealed adverse events (AEs), which were mainly gastrointestinal or systemic in nature. Paik et al. [9] reported that one patient treated with rifaximin complained of abdominal pain. It was easily managed by the physician. No serious events related to rifaximin were reported in this trial. Abdominal pain and diarrhea were also reported in the other two studies and no significant difference was observed when compared with NAD. The incidence of AEs published by Nathan was flatulence (14.3%), diarrhea (10.7%), nausea (14.3%), abdominal pain (8.6%), dyspepsia

| First author (Year) | Control group | Randomization | Blinding | Withdraws and dropouts | Jadad score |
|---------------------|---------------|---------------|----------|------------------------|-------------|
| Mas (2003)[8]       | Lactitol     | Randomization number generated by serial sealed, opaque envelopes | adequately | Clearly reported       | 5           |
| Loguercio(2003)[6]  | Lactitol     | Randomization mentioned but method not specified | adequately | Clearly reported       | 4           |
| Massa(1993)[11]     | Lactulose    | Randomization number table | adequately | NR                     | 4           |
| Giacomo(1993)[10]   | Lactulose    | Randomization mentioned but method not specified | adequately | NR                     | 3           |
| Paik(2005)[9]       | Lactulose    | Randomization number generated by computer | NR       | Clearly reported       | 3           |
| Miglio(1997)[13]    | Neomycin     | Randomization number generated by computer | adequately | NR                     | 4           |
| Nathan(2010)[12]    | Placebo      | Randomization mentioned but method not specified | NR       | Clearly reported       | 3           |

NR: no reported

Table 1 Jadad quality score of randomized controlled trials included in rifaximin study.

| First author (Year) | Study medication | Daily dosage | Duration of the treatment | No. | Type of HE | Evaluation Criteria | Conclusion |
|---------------------|------------------|--------------|---------------------------|-----|------------|---------------------|------------|
| Mas(2003)[8]        | Rifaximin v.s. Lactitol 1.2g/day v.s. 60g/day 5-10 days | 103 | Grade I-II + acute | HE index, mental status, asterixis, EEG ,NH3, NCT | = |
| Loguercio(2003)[6]  | Rifaximin v.s. Lactitol 1.2g/day v.s. 60g/day 15consecutive days/mv3m | 22 | Grade I-II + chronic | Mental status, asterixis, NH3, NCT | ≤ |
| Massa(1993)[11]     | Rifaximin v.s. Lactulose 1.2g/day v.s. 60g/day 15 days | 40 | Grade II-III + chronic | Mental status, ‘A’ cancellation test Reitan test, EEG, HE severity | ≥ |
| Giacomo(1993)[10]   | Rifaximin v.s. Lactulose 1.2 g/day v.s. 120ml/day 90 days | 40 | Stage1 PSE + chronic | Mental status, asterixis, cancellation test, Reitan test, EEG, NH3, PSE severity | ≤ |
| Paik(2005)[9]       | Rifaximin v.s. Lactulose 1.2g/day v.s. 90ml/day 7days | 54 | Grade I-II + acute | HE index, mental status, asterixis, NH3, NCT | = |
| Miglio(1997)[13]    | Rifaximin v.s. Neomycin 1.2g/day v.s. 3g/day 2 weeks/mv6m | 60 | Grade I-II | Neuropsychiatric signs, asterixis, NH3 | = |
| Nathan(2010)[12]    | Rifaximin v.s. Placebo 1.1g/day v.s.1.1g/day 6 months | 299 | Conn score ≥2 + chronic | The Corn score, asterixis grade | > |

HE: hepatic encephalopathy, NCT: number connecting test; PSE:portosystemic encephalopathy, EEG: electroencephalogram

Table 2: Controlled clinical trials of rifaximin in the treatment of HE
(6.4%), ascites (11.4%). Meanwhile, some serious events such as anemia, ascites, esophageal varices, pneumonia were also reported in this study. However, all these studies estimated patients treated with rifaximin were more tolerant than those with NAD [8-9,15].

LOLA

**Background:** LOLA is a stable salt which is composed of the two amino acids L-Ornithine and L-Aspartate. The use of ornithine-aspartate provides substrates for the urea cycle (ornithine) and for the synthesis of glutamine (aspartate, by the transamination to glutamate), while also diminishing ammonium levels. A number of preliminary uncontrolled trials with LOLA had been carried out since 1970s, but there was no clear assessment. However, over the past 10 years, several randomized controlled trials have been conducted [1,2,16].

**Clinical efficacy of LOLA:** Six high-quality trials were enrolled and characteristics were showed in Table 3. One involving 20 patients compared LOLA with lactulose and the other five compared with placebo (Table 4). LOLA is available both in oral or intravenous forms, and the recommended maximal intravenous infusion dose was 5g/h. Kircheis et al. [17] reported 126 patients with minimal or manifest low-grade HE, who were randomized to LOLA group (20g/day infused for over 4 h) or placebo group for 7 days. According to the study, LOLA resulted in significant improvement of mental state grade and portal-systemic encephalopathy index (PSEI) compared with placebo (59% vs. 32%, respectively; p<0.001). Recently, an increasing number of studies were published. In 2006, a randomized lactulose-controlled study with 20 patients of chronic liver disease (3g/three times daily for 2 weeks) indicated that there was no significant prominently difference [16]. In 2010, Schmid et al. [18] performed a double-blind, randomized, placebo-controlled trial which evaluated the effect of LOLA in cirrhotic. It reported LOLA might be superior to placebo and improved Posturography (equilibrium score (ES)) and PSE Syndrome Test (PSE) (ES: 5.3%; PSE: 1.9 vs ES: 3.9%; PSE: 1.3, respectively). A double-blind, randomized, placebo-controlled study was designed by Acharya S.K et al. [19] in order to assess the effectiveness of LOLA in acute liver failure. However, LOLA did not improve clinical symptom, reduce the mortality(mortality: 33.3% in placebo and 42.4% in LOLA) or decrease more ammonia level than placebo(P = 492). Based on these high-quality studies, our meta-analysis showed that LOLA could markedly improve patients with mild to moderate HE [20].

**Adverse events:** Safety was also evaluated as important as efficacy and only a few adverse events such as abdominal pain, nausea and flatulence were frequently reported in these studies [16-18,20-22]. There were no serious adverse events related to LOLA and medications were well tolerated.

**NADs**

NADs, such as lactulose, were used as first-line therapies in 1966

| First author (Year) | Control group | Randomization | Blinding | Withdraws and dropouts | Jadad score |
|---------------------|---------------|---------------|----------|-------------------------|------------|
| Poo(2006)[16]       | Lactulose     | randomization table | NR       | Clearly reported         | 3          |
| Kircheis(1997)[17]  | Placebo       | Computer-generated randomization number | adequately | Clearly reported         | 5          |
| Stauch(1998)[22]    | Placebo       | randomization number generator in blocks of 4 | adequately | Clearly reported         | 5          |
| Ahmad(2006)[21]     | Placebo       | Computer-generated randomization number | NR       | Clearly reported         | 4          |
| Schmid(2010)[18]    | Placebo       | Computer-generated randomization number | adequately | Clearly reported         | 5          |
| Acharya(2009)[19]   | Placebo       | Computer-generated randomization number | adequately | Clearly reported         | 5          |

LOLA: L-Ornithine-L-aspartate, NR: no reported

Table 3: Jadad quality score of randomized controlled trials included in LOLA study.

| First author (year) | Study medication Daily dosage Duration (administration) | No. | Type of HE | Evaluation Criteria | conclusion |
|---------------------|-------------------------------------------------------|-----|------------|---------------------|------------|
| Poo(2006)[16]       | LOLA vs Lactulose 3g tid vs 10ml tid 2 weeks (orally) | 20  | chronic    | Mental state, NCT time, asterixis, fasting NH₃, ECG, PSE, bowel movements and adverse events, quality of life assessment. | =          |
| Kircheis(1997)[17]  | LOLA vs Placebo 20g/day 7 days (infusion) | 126 | chronic    | Postprandial NH₃, NCT time, mental state grades, PSE, safety parameters, and adverse events | >          |
| Stauch(1998)[22]    | LOLA vs Placebo 6g tid vs 5g tid 2 weeks (orally) | 66  | chronic    | Postprandial NH₃, NCT time, mental state grades, PSE, liver blood tests tolerance and adverse events | >          |
| Ahmad(2006)[21]     | LOLA vs Placebo 20g/day 5 days (infusion) | 80  | chronic    | Postprandial NH₃ and mental state grade | >          |
| Schmid(2010)[18]    | LOLA vs Placebo 20g/day 8 days (infusion) | 40  | chronic    | PSE test, peripherd blood and NH₃ | >          |
| Acharya(2009)[19]   | LOLA vs Placebo 30g/day 3 days (infusion) | 201 | acute      | NH₃, adverse events, etiologic evaluation, serum electrolytes, blood urea, serum creatinine, and arterial blood gases | =          |

LOLA: L-Ornithine-L-aspartate, tid: 3 times daily, NCT: number connecting test, PSE:portal systemic encephalopathy, EEG: electroencephalogram

Table 4: Controlled clinical trials of LOLA in the treatment of HE.
and lactitol in 1980 which aimed to reduce intestinal derived production and absorption of ammonia and enhance its elimination [23].

Published studies reported the efficacy were finite for the improvement of HE. A systematic review of 22 RCTs identified that there was insufficient evidence to support or refute the use of NADs for HE and NADs were always served as the comparator in randomized trials on HE [24]. Recently, one trial had been reported that lactulose improved both cognitive function and health-related quality of life in patients with minimal HE [25]. However, no further studies were published.

Flumazenil

From a pathogenetic point of view, it is widely accepted that the cause of HE involved gamma-aminobutyric acid (GABA). GABA and benzodiazepine could make GABA-A receptor complex tick rapidly. Therefore, flumazenil a competitive benzodiazepine antagonist has high affinity with inhibition of GABA receptor binding sites [26-28].

A meta-analysis showed that flumazenil was more preponderant in clinical and ECG improvement of HE than placebo in patients with cirrhosis [29]. In addition, another meta-analysis of 13 randomized trials with 805 patients manifested that flumazenil had an important effect on improvement of HE at the end of treatment (RD 0.28; 95% CI 0.20 to 0.37, eight trials). However, flumazenil had no significant effect on recovery (RD 0.13; 95% CI -0.09 to 0.36, two trials) or mortality (RD 0.01; 95% CI -0.05 to 0.07, 10 trials). It was associated with adverse events, but results were heterogeneous [26]. In summary, flumazenil may benefit patients with HE a lot. However, present studies do not recommend flumazenil routinely. Further studies on large patients are necessary to provide abundant evidence to the effectiveness of flumazenil.

Conclusion

Although there is variability in the improvement of HE, NADs and non-absorbed antibiotics, such as rifaximin, offer a favorable benefit–risk ratio in the improvement of HE. But, they should be recommended carefully in practice. We have entered an exciting phase in the research of HE and further RCTs with power calculation and a multi-centre approach with adequate population number are needed to resolve the heterogeneous results now.

Financial Support

This work was supported by grants from the Scientific Research Foundation of Wenzhou, Zhejiang Province, China (H20090014, Y20090269), Health Bureau of Zhejiang Province (Y2010KBY070), Research Foundation of Education Bureau of Zhejiang Province (Y201009942) and Project of New Century 551 Talent Nurturing in Wenzhou

References

1. Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A (2010) Pharmacotherapy for hepatic encephalopathy. Drugs 70: 1131-1148.
2. Morgan MY, Blei A, Grunigrell K, Jalan R, Kircheis G, et al. (2007) The treatment of hepatic encephalopathy. Metab Brain Dis 22: 389-405.
3. Riggio O, Ridola L (2009) Emerging drugs for hepatic encephalopathy. Expert Opin Emerg Drugs 14: 537-549.
4. Di Piazza S, Gabriella Filippazzo M, Valenza LM, Morello S, Pastore L, et al. (1991) Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 23: 403-407.
5. Leevy CB, Phillips JA (2007) Hospitalizations during the use of rifaximine versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 52: 737-741.
6. Loguercio C, Federico A, De Girolamo V, Ferriera A, Del Vecchio Bianco C (2003) Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 49: 53-62.
7. MacIntyre DO, Eaton-Edwards A (2009) Rifaximin for treatment of hepatic encephalopathy. Am Pharmacother 43: 77-84.
8. Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, et al. (2003) Comparison of rifaximin and lactulose in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 38: 51-58.
9. Paik YH, Lee KS, Han KH, Song KH, Kim MH, et al. (2005) Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 46: 399-407.
10. Giacomli F, FA, Michele N, Oronzo S, Antonella F (1993) Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 4: 57-66.
11. Massa P, Vallerino E, Dodero M (1993) Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res 4: 7-18.
12. Nathan MB, Kevin DM, Arun S, Fred P, Guy N, et al. (2010) Rifaximin Treatment in Hepatic Encephalopathy. N Engl J Med 362: 1071-1081.
13. Miglio F, Valpiani D, Rossellini SR, Ferriera A (1997) Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 13: 593-601.
14. Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, et al. (2008) Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 20: 1064-1070.
15. Bucci L, Palmieri GC (1993) Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 13: 109-118.
16. Poo JL, Gongora J, Sanchez-Avila F, Aguilar-Castillo S, Garcia-Ramos G, et al. (2006) Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol 5: 281-288.
17. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, et al. (1997) Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 25: 1351-1360.
18. Schmid M, Peck-Radosavljevic M, Konig F, Mittermaier C, Gangl A et al. (2010) A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int 30: 574-582.
19. Acharya SK, Bhatia V, Sreenivas V, Kanal S, Panda SK (2009) Efficacy of L-Ornithine-L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 36: 2159-2168.
20. Jiang Q, Jiang XH, Zheng MH, Chen YP (2009) L-Ornithine-L-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol 24: 9-14.
21. Ahmad I, Khan AA, Alam A, Dilesad A, Butt AK, et al. (2008) L-Ornithine-L-aspartate infusion efficacy in hepatic encephalopathy. J Coll Physicians Surg Pak 18: 684-687.
22. Stauch S, Kircheis G, Adler G, Beck K, Dilschumz H, et al. (1998) Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 28: 856-864.
23. Bass NM (2007) Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 25: 3-13.
24. Al-Ali N, Wieland LL, Cuiod G (2004) Absorbable disaccharides for hepatic encephalopathy: a systematic review of randomised trials. BMJ 328: 1046.
25. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, et al. (2007) Efficacy of L-Ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int 30: 574-582.
26. Al-Ali N, Wieland LL, Cuiod G (2004) Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst Rev CD002798.
27. Ahboucha S, Araqi F, Layrargues GP, Butterworth RF (2005) Differential effects of ammonia on the benzodiazepine modulatory site on the GABA-A receptor complex of human brain. Neurochem Int 47: 58-63.

28. Ahboucha S, Butterworth RF (2004) Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint. Metab Brain Dis 19: 331-343.

29. Goulenok C, Bernard B, Cadranel JF, Thabut D, Di Martino V, et al. (2002) Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 16: 361-372.